ProFibrix
Leiden, Zuid-Holland, The Netherlands
About ProFibrix
ProFibrix B.V., a biotech company, creates, develops, and markets products for the hemostasis and regenerative medicine markets. Its products include Fibrocaps, a dry powder topical hemostat and tissue sealant based on a mixture of fibrinogen and thrombin, which stops acute and severe bleeding during surgery or in connection with trauma injury. The company also provides a sterilized single-use delivery device to deliver Fibrocaps to the target tissue area without the need to manipulate the wound in a surgical environment. It offers its products based on human fibrinogen, a natural blood protein for haemostasis, blood clotting, and tissue repair and healing. ProFibrix B.V. was founded in 2004
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $33.0M
- Funding stage: M&A
- Last round: Series B (Aug 2011)
- Website: profibrix.com
- Phone: +31 88 730 8301
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/profibrix-2483786 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.